Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2024-03-25 Director's Dealing
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
113年3月22日內部人設質解質
Director's Dealing Classification · 95% confidence The document is a tabular report showing share pledge information, including details about the pledgor, pledge date, pledged shares, and pledgee. It involves a director (董事長本人) and share pledge data. This matches the category of Director's Dealing, which includes personal share transactions or related share dealings by company directors and executives. The document is short and factual, listing a specific share pledge event rather than a full report or announcement of voting results or capital changes.
2024-03-25 Chinese
112年第4季海外子公司投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment holdings and related financial figures for various overseas subsidiaries of the company 美時. It includes investment amounts, shareholding percentages, and recognized investment gains or losses for the current period and prior year-end. The document is relatively short (2507 characters) and appears to be a regulatory disclosure of investment information rather than a full financial report. There is no indication that this is an annual or interim report, audit report, or earnings release. It is not a meeting material, nor a voting result, nor a management or governance report. The content fits best with a regulatory filing that provides specific investment-related financial data as required by securities regulations. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-03-22 Chinese
112年第4季大陸投資
Regulatory Filings Classification · 95% confidence The document is a detailed tabular disclosure of investment information related to the company's investments in mainland China, including capital amounts, investment methods, and investment income. It includes notes explaining the investment methods and accounting treatments. The document is relatively short (1440 characters) and appears to be a regulatory disclosure of investment details rather than a full financial report or announcement. There is no indication that this is an annual or quarterly report, audit report, or earnings release. It is not a meeting material or voting result. The content fits best with a regulatory filing providing specific investment information as required by authorities. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2024-03-22 Chinese
代重要子公司Alvogen Korea Holdings Ltd.公告監察人當選 名單
Board/Management Information Classification · 100% confidence The document is a short announcement (996 characters) from a listed company (1795 美時) regarding the election of a supervisor (監察人) for its important subsidiary Alvogen Korea Holdings Ltd. It details the change in personnel, including names, dates, and reasons for the change (term expiration). There is no financial data, no report attached or referenced, and no mention of financial results or regulatory filings beyond this personnel change. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management.
2024-03-21 Chinese
代重要子公司Alvogen Korea Holdings Ltd.公告2024年股東 常會重要決議事項
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a formal announcement from a company regarding the important resolutions passed at the 2024 Annual General Meeting (AGM) of its significant subsidiary, Alvogen Korea Holdings Ltd. It lists key decisions such as approval of the 2023 financial statements, election of supervisors, and approval of directors' and supervisors' remuneration. The document is short (666 characters) and focuses on the voting results and decisions made at the AGM rather than providing the full report or detailed financial data. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-03-21 Chinese
代重要子公司Alvogen Korea Co., Ltd.公告董事當選名單
Board/Management Information Classification · 100% confidence The document is a formal announcement from a listed company (1795 美時) regarding the election results of directors for its important subsidiary Alvogen Korea Co., Ltd. It details the names of outgoing and incoming directors, their terms, and other related information. There is no financial data, no report attached or referenced as being published, and no mention of financial results or management discussion. The content clearly relates to changes in the board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is short (1505 characters), consistent with a typical management change announcement rather than a full report.
2024-03-21 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.